Pancreatic Cell News Volume 2.48 | Dec 6 2011

DIABETES

Intravital Imaging of CTLs Killing Islet Cells in Diabetic Mice
Here, researchers report the use of intravital 2-photon imaging in mice to visualize the dynamic behavior of a virally expanded, diabetogenic CTL population in the pancreas at cellular resolution. [J Clin Invest]
Abstract | Press Release

A Small Molecule Differentiation Inducer Increases Insulin Production by Pancreatic ß Cells
Here, researchers probed effects of isoxazoles on human cadaveric islets and MIN6 pancreatic ß cells. [Proc Natl Acad Sci, USA] Abstract

Protein Phosphorylation Involved in the Gene Expression of the Hydrogen Sulphide Producing Enzyme Cystathionine γ-Lyase in the Pancreatic ß-Cell
Researchers examined the mechanisms by which glucose induces cystathionine γ-lyase expression in mouse pancreatic islets and the insulin-secreting cell line MIN6. [Mol Cell Endocrinol] Abstract

Rational Bioprocess Design for Human Pluripotent Stem Cell Expansion and Endoderm Differentiation Based on Cellular Dynamics
Researchers present a predictive bioprocess design strategy employing cell- and molecular-level analysis of rate-limiting steps in human pluripotent stem cell expansion and differentiation, and apply it to produce definitive endoderm progenitors using a scalable directed-differentiation technology. [Biotechnol Bioeng]
Abstract | Press Release

Induction and Selection of Sox17-Expressing Endoderm Cells Generated from Murine Embryonic Stem Cells
Here researchers show the activin A-induced differentiation of mouse embryonic stem cells carrying a homologous dsRed-IRES-puromycin knock-in within the Sox17 locus into the endoderm lineage. [Cells Tissues Organs] Abstract

PANCREATIC CANCER

Therapeutic Efficacy of a Lipid-Based Prodrug of Mitomycin C in Pegylated Liposomes: Studies with Human Gastro-Entero-Pancreatic Ectopic Tumor Models
The purpose of this study was to examine the plasma stability, pharmacokinetics, and antitumor activity of a mitomycin-C lipid-based prodrug formulated in pegylated liposomes in mouse models of human gastroentero-pancreatic tumors. [J Control Release] Abstract

Selective Radiosensitization of p53 Mutant Pancreatic Cancer Cells by Combined Inhibition of Chk1 and PARP1
Researchers hypothesized that inhibition of homologous recombination repair [mediated by checkpoint kinase 1 (Chk1) via AZD7762] and poly (ADP-ribose) polymerase-1 (PARP1) [via olaparib (AZD2281)] would selectively sensitize p53 mutant pancreatic cancer cells to radiation. [Cell Cycle] Abstract

Is the Combination of Chromogranin A and Pancreatic Polypeptide Serum Determinations of Interest in the Diagnosis and Follow-Up of Gastro-Entero-Pancreatic Neuroendocrine Tumors?
The objectives of this study were to evaluate the sensitivity of pancreatic polypeptide (PP) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine tumors and to compare changes in serum CgA and PP levels with the morphological evolution of the tumors. [Eur J Cancer] Abstract

2-Triazenoazaindoles: A Novel Class of Triazenes Inducing Transcriptional Down-Regulation of EGFR and HER-2 in Human Pancreatic Cancer Cells
Researchers found that treatment of cells with AS104 causes significant reduction of cell growth and metabolic activity in four human pancreatic cancer cell lines. [Int J Oncol] Abstract

Serum Deprivation Induces Glucose Response and Intercellular Coupling in Human Pancreatic Adenocarcinoma PANC-1 Cells
This study aimed to investigate whether the previously described differentiating islet-like aggregates of human pancreatic adenocarcinoma cells (PANC-1) develop glucose response and exhibit intercellular communication. [Pancreas] Abstract

FDA Outlines Flexible Approaches for Artificial Pancreas System Clinical Trials, Product Approvals
The U.S. Food and Drug Administration (FDA) issued draft guidance designed to help investigators and manufacturers as they develop and seek approval for artificial pancreas device systems to treat type 1 diabetes. [U.S. Food and Drug Administration] Press Release

Oncolytics Biotech® Inc. Announces Phase II Clinical Trial of REOLYSIN® in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint
Oncolytics Biotech Inc. announced that interim data from a Phase II clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine in patients with advanced pancreatic cancer indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active. [Oncolytics Biotech Inc.] Press Release

Small Grants Program for Cancer Epidemiology (R03) (PAR-12-039) [National Institutes of Health, United States]

Notice of Detailed Budget Correction for NIDDK PAR-11-349: Research Using Subjects from the Type 1 Diabetes TrialNet Natural History Study (Living Biobank) (DP3) and PAR-11-350: Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3) (NOT-DK-12-005) [National Institute of Diabetes and Digestive and Kidney Diseases, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pancreatic cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Fellow – Islet Cell Electrophysiology (Vanderbilt University)    

Professor of Metabolism and Diabetes (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.